Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development
Authors
Keywords
-
Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 93, Issue 6, Pages 502-514
Publisher
Springer Nature
Online
2013-04-15
DOI
10.1038/clpt.2013.54
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inhibition of Renal Glucose Reabsorption: A Novel Strategy for Achieving Glucose Control in Type 2 Diabetes Mellitus
- (2013) Muhammad Abdul-Ghani et al. Endocrine Practice
- Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology
- (2013) N. Benson et al. Interface Focus
- Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
- (2012) Muhammad A. Abdul-Ghani et al. Current Diabetes Reports
- Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes
- (2012) J. Rosenstock et al. DIABETES CARE
- Cross-membrane signal transduction of receptor tyrosine kinases (RTKs): from systems biology to systems pharmacology
- (2012) Neil Benson et al. JOURNAL OF MATHEMATICAL BIOLOGY
- A mathematical model of the human menstrual cycle for the administration of GnRH analogues
- (2012) Susanna Röblitz et al. JOURNAL OF THEORETICAL BIOLOGY
- Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain
- (2012) Bernard P. Roques et al. NATURE REVIEWS DRUG DISCOVERY
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- The synthesis and in vivo evaluation of [18F]PF-9811: a novel PET ligand for imaging brain fatty acid amide hydrolase (FAAH)
- (2012) Marc B. Skaddan et al. NUCLEAR MEDICINE AND BIOLOGY
- Inhibitors of endocannabinoid breakdown for pain: Not so FA(AH)cile, after all
- (2012) Vincenzo Di Marzo PAIN
- An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee
- (2012) John P. Huggins et al. PAIN
- Mechanism-Based Approach to the Economic Evaluation of Pharmaceuticals
- (2012) Joshua Pink et al. PHARMACOECONOMICS
- Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions
- (2012) Oscar Sasso et al. PHARMACOLOGICAL RESEARCH
- Pharmacodynamic Model of Sodium–Glucose Transporter 2 (SGLT2) Inhibition: Implications for Quantitative Translational Pharmacology
- (2011) Tristan S. Maurer et al. AAPS Journal
- A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
- (2011) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
- (2011) Roy Fleischmann et al. ARTHRITIS AND RHEUMATISM
- Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects
- (2011) Gai Ling Li et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Impact of Pharmacometric Analyses on New Drug Approval and Labelling Decisions
- (2011) Joo Yeon Lee et al. CLINICAL PHARMACOKINETICS
- Therapeutic Index of Anticoagulants for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose–Response Meta-Analysis
- (2011) J W Mandema et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Comparative Efficacy and Effectiveness: An Opportunity for Clinical Pharmacology
- (2011) R L Lalonde et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
- (2011) S. Sha et al. DIABETES OBESITY & METABOLISM
- Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival
- (2011) Paul Morgan et al. DRUG DISCOVERY TODAY
- Mechanistic and Pharmacological Characterization of PF-04457845: A Highly Potent and Selective Fatty Acid Amide Hydrolase Inhibitor That Reduces Inflammatory and Noninflammatory Pain
- (2011) K. Ahn et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Diabetes area participation analysis: a review of companies and targets described in the 2008 – 2010 patent literature
- (2010) Philip A Carpino et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Single-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus
- (2010) Elizabeth K. Hussey et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor
- (2010) Douglas S. Johnson et al. ACS Medicinal Chemistry Letters
- Can Animal Models of Disease Reliably Inform Human Studies?
- (2010) H. Bart van der Worp et al. PLOS MEDICINE
- The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
- (2009) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling
- (2009) Mark C. Peterson et al. BONE
- Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A Semi-Mechanistic Model of CP-690,550-Induced Reduction in Neutrophil Counts in Patients With Rheumatoid Arthritis
- (2009) Pankaj Gupta et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
- (2008) J. F. List et al. DIABETES CARE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started